This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Dyax's CEO Presents At Deutsche Bank AG Health Care Conference (Transcript)

Dyax Corp. (DYAX)

Deutsche Bank AG Health Care Conference Call

May 7, 2012 9:20 am ET


Gustav A. Christensen – President and Chief Executive Officer


Robyn Karnauskas – Deutsche Bank Securities


Robyn Karnauskas – Deutsche Bank Securities

Good morning. My name is Robyn Karnauskas, I am the Deutsche Bank Biotech analyst. Next we have Dyax Corporation, speaking for Dyax is Gustav Christensen, President and CEO. And for those of you who are listening through the webcast, do you have any questions you can email me at or we have a new way to access the conference and ask questions synonymously at and we can see your questions without knowing who you are. Questions or comments we'll read towards the end.

With that, I’ll turn it over to Gustav.

Gustav A. Christensen

Thank you very much Robyn. I want to thank Deutsche Bank for having us back again at this Annual Healthcare Conference, it’s always a pleasure. I want to thank you for sitting in on the Dyax presentation this morning, I’m looking forward to update you on Dyax and tell you why we are excited about Dyax and it’s future and it’s value proposition.

So it is a presentation in which I will be making some forward-looking statements and therefore call your attention to the Safe Harbor statement.

So Dyax is today a fully integrated biopharmaceutical company, while there are few who have made that for. We have done so by developing and evolving our phage technology phage display, a technology that not only Dyax have utilized to discover up our own products. But build a solid licensing business where other people are using the product and have developed a large pipeline. So where Dyax we have discovered developed and are now selling our first pharmaceutical product KALBITOR for hereditary angioedema attacks. We’re working on phase II studies to expand the label, the first one in ACE inhibitor-induced angioedema they met a medical problem.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%
TSLA $240.76 0.00%
YHOO $36.60 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs